+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025

  • ID: 5232476
  • Report
  • January 2021
  • Region: Global
  • 125 Pages
  • Kuick Research
UP TO OFF
until Apr 30th 2021

FEATURED COMPANIES

  • Amgen
  • Codiak Biosciences
  • Eli Lilly
  • Johnson & Johnson
  • Mirati Therapeutics
  • Oblique Therapeutics

Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025 Report Highlights:

  • KRAS Inhibitors Market Opportunity: > USD 1 Billion by 2025
  • Initially US To Dominate KRAS Inhibitors Market: >90% Market Share
  • Number of KRAS Inhibitors In Trials: > 20 Drugs
  • Highest Phase of Clinical Development: Phase-III Study
  • Solid Tumors Targeted Drugs Dominating The Clinical Trials
  • Global KRAS Inhibitors Market Trends & Dynamics
  • Global KRAS Inhibitors Market Future Opportunity Outlook

The accelerating pace of the cancer cases at global level has led to the arrival of a unique and application-based therapy market, known as KRAS inhibitors. In the past few years, the therapy has been able to show favorable response involving the cell cycle, which is the ultimate target of the cancer cells for continue its proliferation and division in the patients. A cluster of innovative drugs that target KRAS protein has been developed by the researchers and bunch of novel product candidate targeting KRAS protein is currently active in the clinical trials. It can be stated for KRAS inhibitors that it is among the top emerging sectors of the cancer therapeutics market which is due to the splendid research and development pipeline associated with the market. The entire market associated with KRAS inhibitors, in a very short period of time has been able to shift the entire cancer landscape, thus resulting in the standard care of cancer treatment with appropriate opportunities to the patients and the investors.

The drugs developed under the market, inhibits KRAS protein and further the important signaling pathways, ultimately leading to the cell cycle arrest and killing of the cancer cells. Such switching on and off of the cell cycle with the help of hundreds of KRAS inhibitors developed by the researchers is estimated to improve the overall paradigm for efficient targeting, minimal side-effect development, increased effectiveness and efficiency against different types of tumor antigens. The overall increase in the spending for research-based formulas for KRAS inhibitors is also estimated to develop a market that is worth trillions of dollars and decrease the burden that is getting reflected in the cancer therapeutics market with respect to efficient targeting of the cancer cells.

Despite having numerous challenges which were set by the already driven cancer therapies in the market such as chemotherapy or radiation therapy, the novel KRAS inhibitor market has made its impact on the overall running paradigm of cancer therapeutics at global level. The pharmaceutical research sector affiliated with KRAS inhibitor market has weathered down the complex challenges of developing drug candidates with 100% efficacy.

Now-a-days, the KRAS inhibitor market at global level is getting adjoined with novel techniques and technologies that are apparently leading to reinventing the entire cancer market and research-based sector. No doubt, the entire market has led to an opening of novel frontiers that could unravel the complex mechanism of cancer cells and how it could get regulated by controlling the proteins responsible for cell cycle. In addition to this, some of the parameters that are leading to the exponential growth of the market in the past few years include: healthcare benefits associated with the drug candidates and increased awareness about the side-effects of old and traditional cancer therapies such as chemotherapy.

As per the Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025 report findings, it can be estimated that the market is completely getting catalyzed by the increased applications of healthcare benefits and variety of disruptive technologies and drug candidates that are available in the market for different types of tumor antigens. In the novel cancer therapeutics market, partly driven by KRAS inhibitor is believed to be overcoming all the challenges that were difficult to crack before the arrival of the KRAS inhibitor therapy.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Codiak Biosciences
  • Eli Lilly
  • Johnson & Johnson
  • Mirati Therapeutics
  • Oblique Therapeutics

1. Introduction to KRAS Inhibitors
1.1 Overview
1.2 Evolution of KRAS Inhibitors

2. Role of KRAS Inhibitors in Cancer

3. KRAS Inhibitors - Mode of Action

4. KRAS Inhibitors For Targeting Lung Cancer
4.1 Impact of KRAS Inhibitors on Lung Cancer
4.2 Ongoing Research & Development
4.2.1 AMG 510 (Sotorasib)
4.2.2 MRTX849 (Adagrasib)
4.2.3 Other Investigational KRAS Inhibitors for Lung Cancer

5. KRAS Inhibitors in Pancreatic Cancer
5.1 Role of KRAS Inhibitors in Pancreatic Cancer
5.2 Recent Advancement in Pancreatic Cancer Targeting KRAS Inhibitors

6. KRAS Inhibitors for Colorectal Cancer
6.1 Potential of KRAS Inhibitors Against Colorectal Cancer
6.2 Ongoing Research & Development

7. KRAS inhibitors For Other Cancers
7.1 Potential of KRAS Inhibitors as Hematological Cancer Therapeutics
7.2 KRAS inhibitors in Prostate Cancer
7.3 KRAS Inhibitors for Gastric Cancer
7.4 KRAS Inhibition in Endometrium Cancer
7.5 Role of KRAS Inhibitors in Brain Cancer

8. Global KRAS Protein inhibitors Clinical Trials Indicators
8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Patient Segment

9. Global KRAS Protein Inhibitors Clinical Pipeline By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III

10. Global KRAS Inhibitors Market Analysis: Current Scenario

11. Global KRAS Inhibitors Market Trends
11.1 Revolution Medicines’ KRAS-G12(ON) Inhibitor Shows Prominent Anti-Tumor Activity
11.2 Boehringer Ingelheim & Mirati Therapeutics Collaborated to Study Combinational KRAS Inhibitor Therapy
11.3 Merck Signed a Licensing Deal with Taiho & Astex for Developing KRAS Targeting Therapies
11.4 Strata Collaborated with Mirati Therapeutics for Conducting Trial of MRTX849
11.5 Revolution Medicine Collaborated with Amgen to Evaluate SHP2 & KRAS Inhibitors Combinational Therapy
11.6 Oncogenuity – New Player in KRAS Inhibitor Development
11.7 Miratis & Novartis Collaborated to Assess KRAS Inhibitor Based Combinational Therapy

12. Global KRAS Inhibitors Market Dynamics
12.1 Driving Factors for KRAS Inhibitor Market
12.2 Challenges for KRAS Inhibitors Market

13. Global KRAS Inhibitors Market Future Opportunity Outlook

14. Competitive Landscape
14.1 Amgen
14.2 Mirati Therapeutics
14.3 Revolution Medicines
14.4 Boehringer Ingelheim
14.5 Merck
14.6 Moderna
14.7 Silenseed
14.8 Johnson & Johnson
14.9 Eli Lilly
14.10 Oblique Therapeutics
14.11 Cotinga Pharmaceuticals
14.12 Codiak Biosciences
14.13 Gilead

List of Figures
Figure 1-1: RAS Mutation – Frequency of KRAS Mutation v/s HRAS & NRAS Mutations
Figure 1-2: Historical Development of KRAS Inhibitors
Figure 2-1: KRAS Mutational Frequency by Organs (%)
Figure 2-2: Roles of KRAS Inhibitors in Cancer Treatment
Figure 3-1: General Mechanism of KRAS Inhibitors against Cancer
Figure 3-2: Targeting Approaches of KRAS Inhibitors
Figure 3-3: Direct Targeting of Mutant KRAS
Figure 3-4: Targets for Modifying the KRAS Membrane Association
Figure 4-1: Global – Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
Figure 4-2: Global – Lung Cancer Incidence by Type (%), 2020
Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer
Figure 4-4: Investigational KRAS Inhibitors for Lung Cancer
Figure 4-5: Codebreak 200 Trial – Study Initiation & Expected Completion Year
Figure 4-6: Codebreak 105 Trial – Study Initiation & Expected Completion Year
Figure 4-7: Codebreak 101 Trial – Study Initiation & Expected Completion Year
Figure 4-8: Krystal 7 trial – Study Initiation & Expected Completion Year
Figure 4-9: Krystal 1 trial – Study Initiation & Expected Completion Year
Figure 4-10: Krystal 2 trial – Study Initiation & Expected Completion Year
Figure 4-11: BI-1701963 Phase I Trial – Study Initiation & Expected Completion Year
Figure 4-12: mRNA-5671 Phase I Trial – Study Initiation & Expected Completion Year
Figure 4-13: Mechanism of BI-2852 against Lung Cancer
Figure 5-1: Global – Newly Diagnosed Cases & Deaths related to Pancreatic Cancer, 2020
Figure 5-2: Ideal Targets of Inhibiting KRAS Mutation of Pancreatic Cancer
Figure 5-3: Role of KRAS Inhibitors in Pancreatic Cancer
Figure 5-4: Investigational KRAS Inhibitors for Pancreatic Cancer
Figure 5-5: siG12D LODER Phase II Trial – Study Initiation & Expected Completion Year
Figure 5-6: iExosomes Phase I Trial – Study Initiation & Expected Completion Year
Figure 5-7: KRAS mTCR PBL Phase I/II Trial – Study Initiation & Expected Completion Year
Figure 6-1: Global – Newly Diagnosed Cases & Deaths related to Colon Cancer (Million), 2020
Figure 6 -: Global – Newly Diagnosed Cases & Deaths related to Rectum Cancer (Million), 2020
Figure 6-3: Ideal Targets for Inhibiting KRAS Mutation of Pancreatic Cancer
Figure 6-4: Investigational KRAS Inhibitors for Colorectal Cancer
Figure 7-1: Global – Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 7-2: Global – Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 7-3: Frequency of KRAS Mutation in Hematological Cancer (%)
Figure 7-4: Global – Newly Diagnosed Cases & Deaths related to Prostate Cancer (Million), 2020
Figure 7-5: Global – Number of Newly Diagnosed Gastric Cancer Cases & Deaths, 2020
Figure 7-6: Global – Number of Newly Diagnosed Cases of Endometrial Cancer by Type, 2020
Figure 7-7: Global – Number of Deaths of Endometrium Cancer by Type, 2020
Figure 7-8: Global – Newly Diagnosed Cases & Deaths related to Brain Cancer, 2020
Figure 8-1: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2020 -2025
Figure 8-2: Global - KRAS Protein inhibitors Clinical Trials by Country, 2020 -2025
Figure 8-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2020 -2025
Figure 8-4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2020 -2025
Figure 8-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2020 -2025
Figure 12-1: Drivers for KRAS Inhibitor Market
Figure 12-2: Challenges for KRAS Inhibitor Market
Figure 12-3: Global – Estimated Monthly Treatment Cost of AMG 150 v/s Other Cell Signal Targeting Therapeutics
Figure 13-1:– US - Expected Monthly & Full Treatment Cost of KRAS Inhibitors (US$), November’2020
Figure 13-2: Global – Estimated KRAS Inhibitors Market (US$ Million), 2023 - 2025
Figure 13-3: US v/s Non US Markets - KRAS Inhibitors Market Share (%), 2023 - 2025

Note: Product cover images may vary from those shown
  • Amgen
  • Boehringer Ingelheim
  • Codiak Biosciences
  • Cotinga Pharmaceuticals
  • Eli Lilly
  • Gilead
  • Johnson & Johnson
  • Merck
  • Mirati Therapeutics
  • Moderna
  • Oblique Therapeutics
  • Revolution Medicines
  • Silenseed
Note: Product cover images may vary from those shown
Adroll
adroll